For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Crinetics Pharmaceuticals, Inc.

USPTO Granted Patents = 31

EPO Patents = 9

Trademarks = 5

Forward Citations = 106

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

Yunfei Zhu (24 out of 24 patents)

Sangdon Han (18 out of 40 patents)

Sun Hee Kim (18 out of 24 patents)

4. Jian Zhao (17 out of 49 patents)

5. Shimiao Wang (14 out of 14 patents)

6. Jayachandra P Reddy (3 out of 4 patents)

7. Mahmoud Mirmehrabi (2 out of 15 patents)

8. Ian Yates (2 out of 3 patents)

9. Gerald Burke (2 out of 2 patents)

10. Hannah Bulovsky (2 out of 2 patents)

11. Kyle Kyburz (2 out of 2 patents)

12. Clayton Tyler (2 out of 2 patents)

13. Mi Chen (2 out of 28 patents)

14. Peter Baruch Mueller (1 out of 13 patents)

15. Zhiyong Chen (1 out of 13 patents)

31 patents: Sort by Forward Citations

1. 12492181 - Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-12-09),

2. 12479828 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-11-25),

3. 12479825 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-11-25),

4. 12466829 - Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2025-11-11),

5. 12280046 - Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease (2025-04-21),

6. 12208092 - Compositions and methods for administering paltusotine to patients with hepatic impairment (2025-01-28),

7. 12134610 - Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof (2024-11-05),

8. 11957674 - Formulations of a somatostatin modulator (2024-04-16),

9. 11834462 - Somatostatin modulators and uses thereof (2023-12-05),

10. 11773076 - Crystalline forms of a somatostatin modulator (2023-10-03),

11. 11608335 - Somatostatin modulators and uses thereof (2023-03-21),

12. 11566015 - Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof (2023-01-31),

13. 11479540 - Nonpeptide somatostatin type 5 receptor agonists and uses thereof (2022-10-25),

14. 11414397 - Somatostatin modulators and uses thereof (2022-08-16),

15. 11266641 - Formulations of a somatostatin modulator (2022-03-08),

Crinetics Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's pipeline includes potential treatments for acromegaly, Cushing's disease, neuroendocrine tumors, and other endocrine disorders. With its innovative approach, Crinetics Pharmaceuticals aims to improve the lives of patients with unmet medical needs in the endocrine field.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

31 Patents

#196 in San Diego, CA

#2,529 in California

#10,562 in US

#20,639 in the World

San Diego, CA, United States of America

Crinetics Pharmaceuticals, Inc.

Forward Citations = 106

28 inventors:

Yunfei Zhu (24 out of 24 patents)

Sangdon Han (18 out of 40 patents)

Sun Hee Kim (18 out of 24 patents)

4. Jian Zhao (17 out of 49 patents)

5. Shimiao Wang (14 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…